During this year´s AACR Annual Meeting, Washington DC, April 6 -10, ecancer caught up with VHIO´s Laura Soucek, PI of the Mouse Models of Cancer Therapies Group, to discuss her group´s pioneering work on Myc inihibition in pre-clinical mouse models.
Related Posts
Gene expression improves the definition of a breast cancer subtype
ØThe study conducted by the Vall d’Hebron Institute of Oncology (VHIO) in conjunction with the GEICAM cooperative group and other American and Canadian researchers has led to a change in the definition of hormone-sensitive breast tumours
20 Dec 2012
Last month´s ESMO Congress: ecancerTV coverage of VHIO faculty who chaired, presented, delivered and discussed
Recently celebrated in Copenhagen, Denmark, 07-11 October 2016, the 2016 Congress of the European Society for Medical Oncology (ESMO), surpassed…
10 Nov 2016
Biosimilars create opportunities for sustainable cancer care
Source: the European Society for Medical Oncology (ESMO) Lugano, Switzerland, 18 January, 2017 – Biosimilars create opportunities for sustainable cancer…
18 Jan 2017
In full swing: "la Caixa" Banking Foundation´s Los Imprescindibles campaign
Currently broadcasting across various Spanish media channels, the “la Caixa” Banking Foundation, one of VHIO´s patrons and invaluable supporters, has…
27 Sep 2017
American Association for Cancer Research Elects Dr. José Baselga as President-elect 2014-2015
PHILADELPHIA — The members of the American Association for Cancer Research (AACR) have elected José Baselga, M.D., Ph.D., physician-in-chief at Memorial Sloan Kettering Cancer Center in New York, N.Y., as their president-elect for 2014-2015. Baselga is an internationally recognized physician-scientist whose research focuses on the clinical development of novel molecularly targeted agents for the treatment of cancer, particularly breast cancer.
18 Mar 2014
Election results just in: Solange Peters to take the reins as ESMO President for the 2020-2021 term
The European Society for Medical Onocology (ESMO) has just announced that the President for 2020-2021 is Solange Peters, MD, PhD,…
28 Jun 2017
Fero Community´s annual fundraising gala dinner and award ceremony: a record-breaking celebration
Celebrated last week and returning to the stunning Oval Room of Catalonia´s National Museum of Art (MNAC), Fero´s community joined…
15 May 2017
Study describes phenomenon of resistance to novel therapy for advanced lung cancer
• Resistance to targeted therapies for lung cancer, the most common cancer worldwide, represents one of the major limitations in…
05 May 2015
VHIO collaborates in study identifying a novel therapeutic target for triple-negative breast cancer
• The PIM1 proto-oncogene evidenced as new therapeutic target through which to sensitize triple-negative breast tumours to chemotherapy• PIM1…
05 Nov 2016
Driving a novel therapy against glioblastoma: VHIO´s Laura Soucek awarded BBVA Foundation Grant to validate peptides targeting Myc
• The BBVA Foundation backs research aimed at preclinically validating recently reported findings that established Omomyc as a potential…
09 Oct 2015
REGISTRATION & ABSTRACT SUBMISSION NOW OPEN: VHIO´s Special Symposium on Towards Predictive Cancer Models, 26 – 27 May, 2016
On behalf of our two Co-Chairs, Joaquín Arribas, Director of Preclinical Research at VHIO, and Laura Soucek, Principal Investigator of…
15 Jan 2016
The 2013 Georges Mathé Prize awards innovative research into brain tumors
The Prize, supporting translational research of excellence, was established in memory of the pioneer of cancer research in France, Georges…
14 Oct 2013
ecancer TV´s interview with Joan Seoane: driving discovery to more precisely characterize, track and treat glioblastoma
During the recently celebrated 24th Biennial Congress of the European Association for Cancer Research (EACR), 09 – 12 July, Manchester…
25 Jul 2016
Gene expression refines triple-negative breast cancer diagnosis
Researchers at the Vall d’Hebron Institute of Oncology (VHIO) and University of North Carolina have conducted a study on gene…
25 Feb 2013
NEJM:Two-drug combination, nab-paclitaxel and gemcitabine, improves survival in pancreatic cancer
• Investigators at the Vall d´Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO), have participated in an…
17 Oct 2013
